Glioma represents the most common central nervous system cancer in adults. The current classification scheme uses molecular alterations, particularly IDH1.R132H, to stratify lesions into distinct ...

The currently enrolling SIGMA trial will now include patients with grade 2 astrocytoma with high-risk features in the maintenance setting, in addition to previously eligible patients with high-grade ...

Leonora Balaj, PhD, an investigator in the department of Neurosurgery at Massachusetts General Hospital and an assistant professor of Neurosurgery at Harvard Medical School, is co-senior author of a ...

Leonora Balaj, PhD, an investigator in the department of Neurosurgery at Massachusetts General Hospital and an assistant professor of Neurosurgery at Harvard Medical School, is co-senior author of a ...

This study performed a comprehensive analysis of cuproptosis-related genes (CRGs) in IDH1-mutant glioma samples from the TCGA database. Two novel IDH1-mutant glioma subtypes were identified based on ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first ...

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients.

Voranigo is rapidly adopted for IDH-mutated glioma, addressing unmet needs and shifting towards earlier intervention. Retrospective analysis identified 520 patients treated with Voranigo, with 41% ...

HOUSTON -- Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to a follow-up ...

Biomarker testing, particularly IDH1 status, should be linked to diagnosis refinement, prognostication, and treatment selection, with explicit discussion of result implications and any need for ...